CELL RECEPTOR DEVELOPS A NOVEL THERAPY FOR HIGH MEDICAL NEED: CANCER AND AUTOIMMUNE DISEASES.

Cell Receptor, a burgeoning Geneva-based company with a subsidiary in Kiel, Germany, has innovative insights into cell biological processes that enable ground-breaking clinical advances in oncology and autoimmune diseases.

Existing cancer treatments are often associated with severe side effects and, after an initial tumor response, frequently fail to be sufficiently compelling. The resulting chemoresistance is regularly accompanied by the formation of metastases, which can be fatal. The reasons for this lie in the metabolism of the tumor cells: To grow, cells depend on a signaling process outside the cell. However, classic cancer drugs work inside the cell, not outside. Well supplied from outside, the cancer cell can often bypass the effect of the anti-cancer drugs.

Cell Receptor is introducing a new treatment in oncology that blocks growth signaling. At one point, this signaling process is the same for all growing cells. This point is a bottleneck that well-tolerated agents can plug into.

Our well-tolerated method is effective and will herald a new era in oncology by reducing unwanted treatment side effects and preventing conventional treatment failure in the majority of cancer cases.

Every growing cell, including tumor cells, requires platelets to divide. These platelets provide the cells with signaling agents that enable cell growth and help them escape the immune system. They also protect circulating tumor cells from shear forces. We have discovered how to block this contact to prevent the growth of tumor cells and, in particular, metastasis and chemoresistance. Thus, we met a twofold urgent need in medicine and opened up promising prospects for the future.

See this article: https://www.nature.com/articles/d43747-021-00133-8

#cellreceptor #cancer treatment #oncology                                    Member of